References
- Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006;109:366–98
- Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Ann Rev Biochem 2007;76:481–511
- Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 2012;165:1288–305
- Liao F, Zhang XP, Zhou QX, et al. Assay of adenylyl cyclase activity by ion-exchange high-performance liquid chromatography. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2000;32:661–4
- Huang W, Zhang Y, Sportsman, JR. A fluorescence polarization assay for cyclic nucleotide phosphodiesterases. J Biomol Screen 2002;7:215–22
- Tian L, Wang RE, Fei Y, Chang YH. A homogeneous fluorescent assay for cAMP-phosphodiesterase enzyme activity. J Biomol Screen 2012;17:409–14
- Chock SP, Huang CY. An optimized continuous assay for cAMP phosphodiesteraseand calmodulin. Anal Biochem 1984;138:34–43
- Webb MR. A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems. Proc Natl Acad Sci USA 1992;89:4884–7
- Zhu S, Gan ZY, Li ZR, et al. The measurement of cyclic nucleotide phosphodiesterase 4 activities via the quantification of inorganic phosphate with malachite green. Anal Chim Acta 2009;636:105–10
- Zhu S, Yang GQ, Yang XL, et al. Soluble expression in E. coli of active human cyclic nucelotide phosphodiesterase isoform 4B2 in fusion with maltose-binding-protein. Biosci Biotechnol Biochem 2009;73:968–70
- Feng J, Chen Y, Pu J, et al. An improved malachite green assay of phosphate: mechanism and application. Anal Biochem 2011;409:144–9
- Zhang HT. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des 2009;15:1688–98
- Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 2012;12:275–86
- Rocque WJ, Holmes WD, Patel IR, et al. Detailed characterization of a purified type 4 phosphodiesterase, HSPDE4B2B: differentiation of high- and low-affinity (R)-rolipram binding. Protein Expr Purif 1997;9:191–202
- Hoffmann R, Wilkinson IR, McCallum JF, et al. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem J 1998;333:139–49
- Marblestone JG, Edavettal SC, Lim Y, et al. Comparison of SUMO fusion technology with traditional gene fusion systems: enhanced expression and solubility with SUMO. Protein Sci 2006;15:182–9
- Wang Z, Li H, Guan W, et al. Human SUMO fusion systems enhance protein expression and solubility. Protein Expr Purif 2010;73:203–8
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–54
- Liu H, Yang X, Liu L, et al. Spectrophotometric-dual-enzyme-simultaneous assay in one reaction solution: chemometrics and experimental models. Anal Chem 2013;85:2143–54